secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001558370-22-017302
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering Q3 net loss $12.8M; IMM-1-104 IND cleared, trial recruiting; cash runway into Q3 2024
--------------------------------------------------------------------------------

- Net loss $12.8M ($0.49/share) vs $8.5M ($0.47) YoY; R&D $9.4M, G&A $3.8M.
- Cash and marketable securities $117.2M as of Sept 30, 2022, down from $150.2M at Dec 31, 2021.
- IND for IMM-1-104 cleared Sept 2022; Phase 1/2a trial recruiting, first patient expected Q4 2022.
- Preclinical data on IMM-6-415 presented at SITC; IND submission expected Q4 2023.
- FY 2022 GAAP operating expense guidance reduced to $53-56M from $55-60M; cash runway into Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000155837022017302/0001558370-22-017302-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000155837022017302/imrx-20221110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-017302

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer